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Abstract
The identification of genes for monogenic disorders has proven to be highly effective for understanding disease
mechanisms, pathways and gene function in humans. Nevertheless, while thousands of Mendelian disorders have not yet
been mapped there has been a trend away from studying single-gene disorders. In part, this is due to the fact that many of
the remaining single-gene families are not large enough to map the disease locus to a single site in the genome. New tools
and approaches are needed to allow researchers to effectively tap into this genetic gold-mine. Towards this goal, we have
used haploid cell lines to experimentally validate the use of high-density single nucleotide polymorphism (SNP) arrays to
define genome-wide haplotypes and candidate regions, using a small amyotrophic lateral sclerosis (ALS) family as a
prototype. Specifically, we used haploid-cell lines to determine if high-density SNP arrays accurately predict haplotypes
across entire chromosomes and show that haplotype information significantly enhances the genetic information in small
families. Panels of haploid-cell lines were generated and a 5 centimorgan (cM) short tandem repeat polymorphism (STRP)
genome scan was performed. Experimentally derived haplotypes for entire chromosomes were used to directly identify
regions of the genome identical-by-descent in 5 affected individuals. Comparisons between experimentally determined and
in silico haplotypes predicted from SNP arrays demonstrate that SNP analysis of diploid DNA accurately predicted
chromosomal haplotypes. These methods precisely identified 12 candidate intervals, which are shared by all 5 affected
individuals. Our study illustrates how genetic information can be maximized using readily available tools as a first step in
mapping single-gene disorders in small families.
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Introduction
The identification of genes for Mendelian disorders has been a
highly effective approach for understanding disease mechanisms
and normal gene function [1,2]. One of many examples is the
identification of dystrophin gene as the cause of Duchenne
muscular dystrophy. This initial discovery led investigators to
uncover additional disease genes that cause various forms of
muscular dystrophy by affecting the structure and function of
distinct proteins within the dystrophin-dystroglycan complex [3].
Additionally, single-gene discoveries have also been instrumental
in shedding light on multigenic and sporadic disorders. For
example, adenomatous polyposis coli (APC) mutations in hereditary
colon cancer directly led to the identification of other genes
involved in the more common sporadic and polygenic forms of
colon cancer [4]. It is currently estimated that genes for
approximately 3,705 Mendelian and suspected Mendelian disor-
ders have not yet been mapped [5] and because many familial
disorders have not yet been formally described in the literature, the
number of unidentified single-gene disorders is likely to be grossly
underestimated [2]. Although the identification of the causes of
these disorders will almost certainly have broad and significant
impact on our understanding of the pathophysiology underlying
major disease classes (e.g. neurodegenerative, cancer and heart
disease), there has been a trend away from studying single gene
disorders, in favor of the more common complex diseases. This is
in part due to the fact that many of the remaining single-gene
families are difficult to study because they have rare mutations
and/or are not large enough to map the disease locus to a single
site in the genome. New tools and approaches are needed to
allow researchers to effectively utilize these important families.
Towards this goal, we have used haploid cell lines to
experimentally validate the use of high-density SNP arrays to
define genome wide haplotypes and candidate regions, using a
small ALS family.
Clinically, typical ALS is a neurodegenerative disease selectively
involving upper and lower motor neurons that progresses from
initial symptoms to death in three to five years. The etiology of
most cases of ALS remains obscure, with proposed mechanisms
including viral, autoimmune, excitotoxic, metabolic/mitochondri-
al, toxic or apoptotic processes, protein misfolding or altered
axonal transport [6–9]. There is, however, no conclusive evidence
that any of these pathways are responsible for even a small fraction
of ALS cases.
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history (sALS), ,10% of cases are familial (fALS), generally with
an autosomal-dominant pattern of inheritance [9,10]. While fALS
is uncommon, investigation of families with this disease have
provided significant insight into the causes of ALS. The first
example was the discovery that mutations in the Cu/Zn superoxide
dismutase (SOD1) gene cause ALS1 [11], which is thought to
account for 20–25% of fALS and 1–3% of sALS cases [9,12–14].
Additional genes that cause dominantly inherited forms of
clinically typical ALS include the vesicle associated membrane protein
(VAMP)-associated protein B (VAPB) (ALS8) [15,16], the TAR DNA
binding protein (TARDBP) [17] and the fused in sarcoma/translated in
liposarcoma (FUS/TLS) [18,19].
While these discoveries have been important for increasing
our understanding of the causes of ALS and for developing and
testing various treatment strategies, our understanding of the
molecular underpinnings of ALS is still in its infancy and
identifying additional mutations with forms of ALS that are
clinically similar to sALS is likely to clarify the molecular
pathways involved in these diseases. However, large families with
dominantly inherited ALS are difficult to study because the
lethality of the disease limits the ability to obtain DNA from
affected individuals. Furthermore, family members can be
reluctant to participate in research studies because they do not
want to consider the possibility that they or their children might
be at risk. For these reasons, the novel ALS family (ALS-A) we
have been studying for the past 19 years is of significant scientific
importance (Figure 1). We have collected blood from 14
members of this family, including 5 affected individuals, and as
a first step in positional cloning have used haploid and high-
density SNPs analysis to precisely define all of the regions of the
genome that are shared among affected individuals. Because the
disorder in the ALS-A family is indistinguishable from sALS, the
identification of the genetic cause of this disorder is likely to
provide insight into the pathogenic mechanisms of the more
common sporadic disease which may ultimately lead to more
effective treatments.
Results
The ALS-A Family
A pedigree of the ALS-A family is shown in Figure 1. The
disease in this family is phenotypically indistinguishable from
sALS, and characterized by progressive upper and lower motor
neuron degeneration without the involvement of sensory nerves or
other complex neurological features, such as frontotemporal
dementia (FTD) or Parkinson’s features. Age of onset varies,
ranging from 35 to 73 years. Lifespan after initial diagnosis ranged
from 6 months to 5 years; the individual who lived for five years
had a tracheotomy and mechanical ventilation for approximately
one year. Simulated two point linkage analysis predicts a
maximum logarithm of the odds (LOD) score for the family of
3.17 at H=0.00. The dominant inheritance pattern and number
of meioses predict that ,3% of the diploid genome plus the
mutation is likely to be shared among affected family members
(0.5
‘5). Conversely, if completely informative, unambiguously
defined haplotypes should allow ,97% of the genome which is not
shared by the affected individuals to be excluded. A limitation of
Figure 1. ALS-A Pedigree. Affected individuals are indicated with solid symbols and symbols with a line show the individual is deceased. The
asterisk indicates individuals from whom DNA was collected and the H denotes individuals from whom haploid cell lines were generated. For
confidentiality purposes gender is not indicated.
doi:10.1371/journal.pone.0005687.g001
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777 STRP marker screen and conventional multipoint analysis on
the ALS-A family, is that there is a significant disparity between
the theoretical portion of the genome that should be excluded
from containing the ALS-A locus (.97%), and the portion of the
genome actually excluded (67%). This disparity results because the
markers are not fully informative and haplotypes can not be
distinguished.
Haplotype Analysis: STRP Markers and Haploid DNA
Although haplotype analysis is often used to precisely follow the
segregation of small chromosomal regions, recombination and
uninformative markers have historically made establishing un-
equivocal haplotypes for large chromosomal regions impossible.
To test if obtaining accurate chromosomal haplotypes can be
achieved using high-density SNP arrays and if this would provide
more complete segregation information, we directly compared
high-density SNP genotype analysis with experimentally deter-
mined haplotypes ascertained using a panel of haploid mouse-
human hybrid cell lines generated from ALS-A family members
[20].
Experimental haplotypes were established by generating panels
of 18–37 haploid cell lines for eight family members including five
affecteds. A 777 STRP marker genome scan was performed on
DNA from the haploid cell lines, as well as diploid lymphocyte
DNA. Genotyping results from chromosome separated cell lines
were used to directly define haplotypes for entire chromosomes.
Figure 2 illustrates how haplotype comparisons were used to
identify shared, excluded and ambiguous regions using chromo-
some 17 as an example. Because DNA was not available for
individuals I:1 or I:2, transmitted haplotypes were arbitrarily
assigned to the parental generation by genotyping chromosome
separated cell lines from a single affected individual in generation
II. Specifically, one of the parental chromosomal haplotypes from
generation I was designated by a RED bar and the haplotype
transmitted from the other parent was assigned a YELLOW bar.
Recombinant haplotypes defined by the haploid cell lines of other
members of generation II were used to predict the other two
founder haplotypes (BLUE and GREEN). Haplotypes from
spouses who married into the family and do not contain the
ALS-A mutation are indicated by grey bars. STRP markers were
spaced at ,5 cM intervals and double recombinations were
expected to be infrequent. Genomic intervals that are found
among all five affected individuals are indicated by a shared
chromosomal region of the same color (RED or YELLOW).
Because any of the regions of the genome that are shared (i.e.
identical by descent) among the affected individuals could contain
the mutation, all shared regions are considered candidates. Areas
not shared among all five affected individuals are excluded, while
regions are considered ambiguous if the probability of the double
recombination was greater than 1/100 (the threshold for exclusion
by LOD score analysis) (Figure 2). Diploid genotypes from 777
STRP markers were also analyzed using the parametric multipoint
linkage program VITESSE [21].
Comparison of STRP Haplotype and LOD Score Analyses
Figures 3 and 4 show a comparison of the effectiveness of
multipoint linkage using STRP markers and haploid mapping to
define shared or excluded regions for chromosome 1 and across
the entire genome, respectively. Specifically, three positive LOD
scores were generated for chromosome 1, which correspond to a
shared region (LOD=0.785) and two regions known to be
excluded by haplotype analysis (LOD=0.557 & 0.76) (Figure 3).
This comparison illustrates the problems investigators face when
using small families for linkage analysis —shared and excluded
regions are not accurately defined and candidate regions are not
always easily distinguished. Genome-wide, haploid mapping
identified 10 regions (7.4% of the genome) identical by descent
or shared among the 5 affected individuals and definitively
excluded 83.1% of the genome as unshared (Figure 4). In contrast,
traditional multipoint LOD score analysis using STRP markers on
diploid DNA excluded only 67.1% (LOD,22), failed to identify
any shared regions (LOD.3), and generated suggestive scores
(most between 0.5–1.2) for regions that were both shared and
definitively excluded by haploid analysis. In addition to the shared
regions, haploid mapping identified 24 ambiguous regions
(indicated in grey), which most likely result from an uninformative
marker. The use of haploid cell lines increased the amount of the
genome that could be excluded (83%) in comparison to the
traditional multipoint linkage analysis (67%) and more closely
approximated defining the theoretical portion of the genome that
should be shared or identical by descent among the affected
individuals (7.4% by haploid analysis vs. 3.0% theoretical).
SNP Markers
As a second and parallel approach to maximize the genetic
information from this small ALS family, we investigated the utility
of high density SNP arrays to predict shared haplotypes. While
SNP arrays have typically been used to examine heterogeneous
DNA samples in association studies, we sought to determine
whether this technology would be successful in large scale
haplotype reconstruction in a small family with ethnically similar
individuals. By comparing the haplotypes that were experimentally
derived using haploid cells lines, we were able to test the accuracy
of in silico SNP haplotypes predicted by Allegro [22]. Additionally,
the SNP haplotypes were subsequently used to validate the power
of nonparametric linkage analysis (NPL) of the SNP data to
identify shared regions in small kindreds.
Haplotype Analysis Using SNP Genotypes
Comparison of Experimental and In Silico Defined
Recombinations. Diploid DNA samples from fourteen
members of the ALS-A family were analyzed using the
GeneChip
TM Human Mapping 100 K Set (Affymetrix) and the
resultant data were analyzed using the linkage program Allegro
[22]. Specifically, haplotypes were determined in silico and were
compared with the experimentally defined haplotypes from the
haploid cell lines. Evaluation and comparison of recombination
points revealed that the SNP arrays were able to precisely and
accurately reconstruct haplotypes over large chromosomal regions.
Figure 5 shows the comparison of the experimentally and
predicted recombinations over the entire length of chromosome
22. While the recombination points are essentially the same,
arrows point to deviations between the haploid and SNP methods.
Arrows (1) and (5) specify sites where STRP markers were not
informative but SNPs accurately defined the haplotype and
excluded the regions. Arrows (2) and (4) show regions where a
block of SNPs were not informative and the haplotypes could not
be unambiguously defined. Arrow (3) represents a region where a
double recombination over a small area occurred and was not
detected by the STRPs due to marker spacing.
Comparison of Experimental and In Silico Haplotypes:
Defining Shared Regions. Haplotypes determined from the
SNP analysis were examined and regions shared between all five
affected individuals were then defined across the entire genome.
The SNP method identified a total of 10 shared regions (red), eight
of which were detected using the haploid mapping approach and
an additional 2 regions that were not previously identified
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shared region on chromosome 15 because this small interval is
located between two STRP markers and on chromosome 16
because two corresponding STRP markers were not informative.
Conversely, the SNP method did not detect the shared region on
chromosome 13 or the telomeric shared region on chromosome 16
that were identified by the haploid STRP method. A significant
advantage of the SNP approach was that each of the shared
Figure 3. Chromosome 1 Comparison of Excluded, Shared or Ambiguous Regions for Haploid Mapping vs. Multipoint Linkage
Analysis. Comparison of information obtained from haploid mapping (A) and multipoint linkage analysis of diploid DNA (B) for chromosome 1.
Summaries of the LOD scores are presented in B1 and graphs of the actual LOD scores are illustrated in B2. Regions excluded by haploid mapping or
multipoint linkage analysis (LOD,22.0) are white and ambiguous regions are grey (LOD scores between 22 and +3). Shared regions defined as
identical by descent through haploid mapping or with a LOD score .3.0 are shown in red.
doi:10.1371/journal.pone.0005687.g003
Figure 2. Examples of the Haplotype Analysis. Haplotypes from the founder generation (I) were reconstructed using haplotypes defined by
haploid analysis of generation II (colored either red or blue and yellow or green). In subsequent generations the chromosomal regions inherited from
unrelated members were identified and eliminated from the analysis (variations of grey). Regions that are shared among the affecteds, excluded, or
ambiguous were then directly determined. Where a marker was not fully informative, the founder haplotype was not designated and the region was
subsequently denoted by a question mark. Data presented is from chromosome 17.
doi:10.1371/journal.pone.0005687.g002
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regions were much smaller than those defined by the haploid
STRP approach. Furthermore, the SNP method eliminated nearly
all of the ambiguous regions detected by the STRP markers and
only detected an additional four new ambiguous regions; the high
density of SNP markers significantly cleaned up the data and
removed nearly all ambiguity. Nearing the theoretical value of 3%,
these methods show that approximately 4.7% (142 megabase pairs
(Mb)) of the genome is shared among the five affected individuals.
Table 1 lists the shared regions identified by the two methods and
the ambiguous regions detected by the SNPs, along with the
markers and physical positions of the boundaries for each region.
Parametric and Non-parametric Linkage Analysis
In addition to examining the utility and accuracy of predicted
SNP haplotypes, we also investigated the power of nonparametric
or model free linkage analysis to detect shared chromosomal
regions. The non-parametric linkage analyses (NPL and allele
sharing LOD scores), which perform statistical analysis of an
increase in the number of alleles shared among the affected
individuals with respect to identity by descent (IBD), weigh the
genotypes of affected individuals rather than those of unaffected
individuals; therefore all shared regions have equally high allele
sharing LOD and NPL scores and can be easily identified. Using
the linkage program Allegro [22] we generated both NPL and
allele sharing LODs for all of the autosomal chromosomes, which
are depicted in Figure 7. This method clearly distinguished all ten
regions identified by the SNP haplotypes, confirming the power of
model free analysis in the identification of candidate regions within
small families. Parametric analysis was also performed; because the
genotypes from unaffected, but at-risk individuals were factored
into the calculations not all of the shared candidate regions were
clearly identifiable (Figure S1).
Prioritization of the Shared Regions
As a final step, additional pedigree analysis was done to
prioritize the candidate gene regions to those shared among
affected individuals but absent from older unaffected family
members. Although the range in disease onset is broad in the ALS-
A family (35–73 years), two unaffected elderly individuals, II:3 and
II:9, had no evidence of the disease; neither had signs or symptoms
of ALS when examined (ages 68 and 82, respectively). Addition-
ally, individual II:3 had no signs of ALS when interviewed at age
76, and prior to dying from Alzheimer’s disease at age 90 y,
individual II:9 did not demonstrate ALS symptoms according to
relatives or medical records. There was no evidence of
frontotemporal dementia in the family, including II:9, who had
onset of dementia in the late 80 s, no unusual behavior while
dementing, and responded to anticholinesterase medication.
Although neither II:3 and II:9 showed signs of ALS, the possibility
that they carry/carried the disease gene can not be excluded.
However, the age of these individuals make the risk that they carry
the ALS-A gene quite low, and hence make the regions of the
Figure 4. Genome Comparison of Excluded, Shared or
Ambiguous Regions for Haploid Mapping vs. Multipoint
Linkage Analysis. Comparison of the information obtained from
haploid mapping (A) and multipoint linkage analysis (B) for the entire
genome. Summaries of the LOD scores are presented in B1 and graphs
of the actual LOD scores are illustrated in B2. Regions excluded by
haploid mapping or multipoint linkage analysis (LOD,22.0) are white
and ambiguous regions are grey (LOD scores between 22 and +3).
Shared regions defined as identical by descent through haploid
mapping or with a LOD score .3.0 are shown in red.
doi:10.1371/journal.pone.0005687.g004
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likely to contain the gene. Similarly, regions shared by all five
affected individuals and II:3 or II:9 have a lower probability of
containing the ALS-A gene. Using this approach we have
prioritized the candidate regions into three categories (RI-1-3),
with RI-1 being the most likely (Table 2). Three of these regions/
subregions, which span ,23 Mb, are higher priority regions for
future studies because they are not shared in older unaffected
members of the ALS-A family: the 6p25.3-23 region, ,50% of the
4p15.2-p14 region and ,7% of the 4q32.2-34.3 (Table 2). We
Figure 5. Comparison of Recombination Points Identified by Haploid Mapping and SNPs. Recombinations are depicted for the four
founder chromosomes for chromosome 22. The four founder haplotypes are shown in blue, red, green and yellow and the unaffected chromosomes
are shown in grey. Arrows point to deviations between the haploid (STRPs) (A) and SNP (B) methods. Regions that are designated by a hatched
mixture of two colors result from markers that were not fully informative. The (1) and (5) arrows specify regions where the STRPs were not informative
but the SNPs were able to accurately determine the correct haplotype. The (2) and (4) arrows show regions where a block of SNPs were not
informative and the haplotypes could not be accurately designated. The (3) arrow represents a region where a double recombination over a small
area occurred and was not detected by the STRPs due to marker spacing.
doi:10.1371/journal.pone.0005687.g005
Haplotype Mapping of ALS Gene
PLoS ONE | www.plosone.org 7 May 2009 | Volume 4 | Issue 5 | e5687Figure 6. Physical Location of the Shared Regions. The regions that are shared between the five affected individuals are depicted in red. All
regions that were identified as ambiguous by the SNP method are shown in grey, along with the any corresponding ambiguous regions identified by
the STRP markers. The physical locations of the regions’ boundaries were determined by UCSC Genome Browser and approximate positions are
shown by each region in Mb. The * indicates the chromosome 13 STRP marker gata73A05, which defines the haploid shared region, is at 62.5 Mb and
is not shared by the SNPs at this location. The { symbol denotes an inconsistency between the two methods for the shared region on chromosome
15. While the SNP method identified a shared region, the haploid method identified an ambiguous region with a probability of 1/1000 and was
therefore ruled out.
doi:10.1371/journal.pone.0005687.g006
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individuals and not shared by the two unaffected individuals,
which matches our experimental results almost exactly. The
remaining unaffected individuals within the ALS-A family were
not useful in the prioritization because they are still within the
disease onset range.
Discussion
In linkage studies of large families with Mendelian disorders LOD
scoreanalysisisaneffectivemethodtodefinethediseaselocusi.e.the
single region of the genome that is shared among affected
individuals. However, in small families with limited numbers of
meioses, traditional LOD score analysis using STRP markers is less
informative, often showing suggestive LOD scores for regions of the
genome that should be excluded and missing other regions that may
contain the gene. We have explored methods to maximize the
amount of genetic information that can be derived from a small
family with an autosomal dominant form of ALS and show that
analysis of high density SNP haplotypes are able to precisely define
nearly all regions of the genome that are shared among the affected
individuals. Specifically, we used haploid cell lines to experimentally
demonstrate that high density SNP arrays can be used to accurately
define chromosomal haplotypes, precisely identify shared candidate
regions among affecteds and exclude the remaining regions of
genome that are not shared. Additionally, we show that SNP
genotypes can be accurately analyzed by nonparametric linkage
programs and validate the power of model free analysis to detect
shared regions in small families.
Over the past 20 years, genetic investigations using families with
monogenic disorders have provided unparalleled information into
gene function, normal and pathogenic pathways and disease
mechanisms [1]. Because most of the remaining single-gene
families have rare mutations and/or few affected members, new
strategies are needed to effectively use this valuable resource for
genetic studies. Shifting our expectations from the idea that
mapping single-gene disorders necessarily requires sufficient
meioses to localize the gene to a single site in the genome, to
the idea that small families can also be included in genetic studies if
as a first step all shared regions of the genome can be accurately
defined. Because novel disease genes in small families are likely to
hold key lessons for understanding the molecular pathophysiology
Table 1. Data for the Haploid and SNP Shared Regions and the SNP Ambiguous Regions.
Shared
Method
Identified
Chromosomal
Region
Beginning Boundary
Marker
Physical
Location
Ending Boundary
Marker Physical Location
Haploid 1q24.1-25.3 ATA38A05 164,115,369 AAT200 179,292,171
SNP 1q24.2-25.2 rs952963 165,669,836 rs10489882 176,171,118
Haploid 2p25.1-22.1 D2S423 9,858,029 GATA194B06 41,077,763
SNP 2p25.1-23.3 rs1405948 10,500,611 rs1822300 24,578,289
Haploid 3p26.2-25.3 GATA131D09 4,288,250 ATCT053 10,338,466
SNP 3p26.1-25.3 rs2196302 5,780,096 rs3868891 9,674,059
Haploid 4p15.31-14 GATA70E01 20,722,813 ATCT018 39,814,243
SNP 4p15.2-p14 rs4697055 23,876,434 rs7695130 35,959,708
Haploid 4q32.1-35.1 D4S1629 158,556,255 AATA045 183,213,532
SNP 4q32.2-34.3 rs6811083 162,010,831 rs4234867 178,742,190
Haploid 6p25.3-p22.3 NA 1 D6S1959 20,020,074
SNP 6p25.3-23 NA 1 rs2327869 15,096,746
Haploid 9p24.1-q21.13 D9S2156 7,918,932 AGAT140 78,454,471
SNP 9p23-21.1 rs10491744 12,710,106 rs621277 32,506,864
Haploid 13q21.1-22.1 D13S784 54,003,967 D13S800 72,772,650
SNP 15q12 rs1553890 23,688,680 rs4073083 24,737,820
SNP 16p11.2-q12.1 rs10492807 31,687,619 rs7500906 48,354,332
Haploid 16q24.1-24.3 D16S539 84,943,535 NA 88,827,254
Haploid 17q21.32-24.3 D17S2180 44,028,054 D17S2059 66,012,504
SNP 17q22-24.1 rs716392 50,944,412 rs10514869 60,531,720
Ambiguous Haploid 1p36.22-p36.13 AAT238 10,910,244 TTTA063 16,412,894
SNP 1p36.21 rs848578 12,760,221 rs10492987 15,865,925
SNP 10p13 rs963336 12,964,446 rs552437 13,087,512
SNP 13q21.1 rs7335975 53,714,107 rs9316943 57,196,412
SNP 15q25.2-25.3 rs10520582 82,143,780 rs10520601 84,159,205
SNP 15q25.3 rs2120650 84,419,700 rs4887244 85,147,853
Haploid 16p12.1-q12.1 CATA002Z 23,656,985 GATA143D05 49,152,042
Physical locations were determined using the UCSC Genome Browser (www.genome.ucsc.edu) and the NCBI SNP database (http://www.ncbi.nlm.nih.gov/sites/
entrez?db=snp) was used to convert the SNP ID into the RS nomenclature recognized by the UCSC Browser (March 2006). The STRPs were taken from the Marshfield
screening sets 13 and 52.
doi:10.1371/journal.pone.0005687.t001
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PLoS ONE | www.plosone.org 9 May 2009 | Volume 4 | Issue 5 | e5687Figure 7. Non-parametric LOD Score Analysis of the SNP Genotypes. The SNP genotype data were analyzed by Allegro and non-parametric
LOD scores were generated for each autosomal chromosome. The NPL scores are shown by a black line and the red line represents the allele-sharing
LOD. Chromosomal location is shown along the X-axis.
doi:10.1371/journal.pone.0005687.g007
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investigated and that candidate loci are reported—informed
collaborative efforts will lead to the eventual identification of
these genes.
Towards this effort, we have mapped a rare familial form of
ALS that is clinically similar to sALS. Candidate regions for the
ALS-A gene span 142 Mb of DNA located in twelve intervals.
Three of these regions/subregions, which span ,23 Mb, are
higher priority regions for future studies because they are not
shared in older unaffected members of the ALS-A family. While
the following paragraphs describe the next steps in identifying the
ALS-A gene, similar strategies would be generally applicable to
mapping efforts of any single gene disorder in any similarly small
family. First, newly identified candidate regions can be refined and
prioritized, additional families with similar diseases can be
screened for linkage to separate candidate loci and genes of
interest can be sequenced.
Comparisons of known ALS loci with our newly defined
candidate region show several regions of overlap or possible
overlap. For example, an ambiguous region defined by the haploid
cell lines at 1p36.21 contains the recently identified TARDBP gene.
Mutations in this gene cause a phenocopy of sALS [17], however,
this gene has been ruled out by the SNP haplotype analysis and
sequencing of an affected member of the ALS-A family.
Additionally, our initial mapping showed potential overlap with
the ALS6 gene, which was recently shown to be caused by
mutations in FUS/TLS on 16p11.2 [18,19]. Although ALLE-
GRO predicted a recombination that would rule out FUS/TLS, a
detailed inspection of the 100 K SNP data and genotyping analysis
of additional SNPs in the region showed that FUS/TLS lies within
a region between rs7193224 and rs2141349 where a key affected
recombinant has the unaffected haplotype at rs7193224 and the
affected haplotype at rs2141349, a marker lying very close to
FUS/TLS. Therefore, the FUS/TLS locus cannot be conclusively
excluded from the SNP analysis. Subsequent sequence analyses of
the exons and intron/exon boundaries from an affected individual
found no causative mutations. Additionally, one of the 12
candidate regions overlaps with the ALS-FTD locus on 9p21.3-
13.2 [23–25].
The disease spectrum for both ALS and FTD are still evolving,
and families linked to the ALS-FTD locus on chromosome 9 have
members that present with pure ALS, pure FTD or both [23–25].
Therefore, while members of the ALS-A family have not displayed
symptoms of FTD, this shared region remains a viable candidate.
However, because this region is shared by one of the two
unaffected individuals in generation II (Table 2), the likelihood
that this region contains the mutation is low.
To further refine the ALS-A locus we propose additional
independent linkage studies using other small ALS families with
clinically similar forms of ALS. While many of these additional
families will be even smaller than the ALS-A family, our mapping
study will enable other groups to determine if ALS families they
have collected share any of the candidate ALS-A regions we
describe here. Multiple families with linkage to one of these
regions would provide additional support for prioritizing specific
regions for detailed gene cloning efforts. Additionally, haplotype
conservation could indicate the presence of an ancestral mutation
and potentially pinpoint regions of special interest for sequencing.
As a complementary approach, we have begun examining
candidate genes within shared regions, initially focusing on genes
encoding proteins expressed within the CNS or that act in
pathways implicated in ALS. For example, we sequenced superoxide
dismutase 3 (SOD3) located within the 4p15.2-p14 region, due to the
similarity with SOD1, although no mutations were detected in the
Table 2. Genetic Status of Unaffected Individuals II:3 & II:9 for the Seventeen Shared and Ambiguous Regions.
Shared
Region of
Interest Rank Region
Maximum
Size (Mb)
Unaffected
Individual
Unaffected
Individual
RI-1 6p25.3-23 15.1 Mb
RI-1/2 4p15.2-p14 12.1 Mb P (49.2%) P (6.3%)
RI-1/2 4q32.2-34.3 16.7 Mb P (92.4%)
RI-2 2p25.1-23.3 14.1 Mb X
RI-2 3p26.1-25.3 3.9 Mb X
RI-2 13q21.1-22.1 18.8 Mb X
RI-2 15q12 1.0 Mb X
RI-2 16q24.1-24.3 3.9 Mb X
RI-2 17q22-24.1 9.6 Mb X
RI-2/3 9p23-21.1 19.8 Mb A (12.4%) X
RI-2/3 16p11.2-q12.1 16.7 Mb X P (94.2%)
RI-3 1q24.2-25.2 10.5 Mb X X
Ambiguous RI-3 1p36.21 3.1 Mb X X
RI-3 10p13 0.1 Mb X X
RI-3 13q21.1 3.5 Mb X X
RI-3 15q25.2-25.3 2.0 Mb X X
RI-3 15q25.3 0.7 Mb X X
The letter ‘‘X’’ specifies the region is also shared by the unaffected individual, the letter ‘‘P’’ indicates the region is partially shared and the letter ‘‘A’’ designates the
region is ambiguous. The maximum physical size is shown for each region. The shared regions of interest are classified into three categories based on the genomic
content of the two unaffected individuals (II:3 and II:9). The RI-1 category contains regions that are the most likely to contain the ALS-A gene while the RI-3 category
includes regions that are the least likely to hold the gene.
doi:10.1371/journal.pone.0005687.t002
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careful examination of known genes will not be as complicated in
small gene poor areas (chr.4p), this process will be more difficult in
large gene rich regions, such as the shared interval on
chromosome 6p. Therefore, in addition to targeted gene
sequencing, brute force sequencing of entire shared regions may
be appropriate.
In summary, we have demonstrated through experimentally
derived haplotypes using haploid DNA that dense genomic SNP
arrays can accurately define chromosomal haplotypes in small
families. Additionally, we experimentally validate the power and
effectiveness of model free linkage analysis of SNP genotypes in the
detection of the shared candidate regions. Application of this
rapidly improving technology will enable genetic investigations of
a whole class of families with Mendelian disorders that have
typically been ignored by the scientific community due to their
size. By changing the mapping paradigm from the idea that
families with Mendelian disorders need to be large enough to map
the gene to a single site in the genome, to include the concept that
small families can be useful if all regions that could contain the
gene are identified, we can begin to use a valuable and virtually
untapped resource. Improving the power of mapping single-gene
disorders will uncover new disease pathways and mechanisms and
clarify the pathogenesis of devastating disorders like ALS.
Materials and Methods
Ethics Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. All subjects participating in this
study signed an informed consent form approved by the Human
Subjects Committee at the University of Minnesota. DNA was
extracted from peripheral venous blood using the Gentra Pure-
gene blood kit (Qiagen, Valencia, CA).
Generation of haploid cells lines
Panels of haploid mouse/human hybrid cell lines were
generated at GMP Genetics for eight ALS-A family members
(Figure 1) by electrofusing lymphoblast cells from each individual
with embryonic day 2 (E2) mouse cells, using HAT and geneticin
to select against unfused E2 and lymphoblast cells, respectively
[20,26]. Eighteen to thirty seven cell lines were selected for each
individual. In general, each hybrid cell line should contain 8–14
random human chromosomes, some of which are in the haploid
state while others are diploid. On average, an entire single set of
monosomic chromosomes is represented in ,23 independent cell
lines [26,27].
800 Marker Genome Screen
A 777 STRP marker high-density genome screen was
performed on both diploid and haploid DNA from members of
the ALS-A family using fluorescent technology (Figure 1). The
work was performed by the Center of Medical Genetics,
Marshfield, WI as part of the NHLBI Mammalian Genotyping
Service (Contract Number NO1-HV-48141). Markers were taken
from Marshfield screening sets 13 and 52 and all of the cell lines
generated by GMP Genetics were included in the genome screen.
Amplified DNA from parents of CEPH family 1331 (133101 and
133102) were used as standards for all test samples.
Haplotype Ascertainment
Haplotypes for each individual were directly determined along
entire chromosomes by analyzing the genotypes of cell lines
haploid for each chromosome, including the 22 autosomes and the
X chromosome. The diploid DNA was used as an internal control
for each patient and cell lines monosomic for each chromosome
were selected for further analysis so that each homologue was
represented. For the eight patients in which haploid cell lines were
established, phase was determined for each chromosome using the
two independently represented homologues. However, rarely both
homologues were not present in the monosomic state, in which
case haplotypes were defined by comparing genotypes of the
available haploid cell line with the diploid DNA.
Multipoint LOD Score Analysis
Linkage analysis of the 22 autosomes and the X chromosome
were performed using the computer program VITESSE version 2.0
[21]. Five age-dependent penetrance classes were established for at-
risk unaffected individuals based on the age-at-onset profile for the
family (,20 years, 5%; 20–30 years, 10%; 31–60 years, 50%; 61–70
years, 80%; 71+ years, 90%). Affected individuals and unaffected
spouses were classified separately. The lifetime risk of developing a
phenotypically similar disease, sALS, was estimated to be 1/1000.
Allele frequencies and the order of the microsatellite markers used in
the genome screen were established by Marshfield Genetics.
100 K SNP Screen and analysis
High-density SNP based linkage analysis was conducted using the
GeneChip
TMHumanMapping100 KSet (Affymetrix,Santa Clara,
CA). SNP genotype data were extracted with the following ‘‘cut-off
values’’: call rate of control samples .0.95, p value of HWE (Hardy-
Weinberg equilibrium test) in control samples .0.05, MAF (minor
allelefrequencies)ofcontrol samples .0,and confidencescores of all
family members ,0.1. Control samples were collected from 24
healthy Japanese individuals. SNPs were selected to keep the inter-
marker distance at approximately 100 kb. Parametric and non-
parametric multipoint linkage analyses were performed using the
Allegro version 2.0 program [22]. Penetrance classes were set as
described above, and disease gene frequencies were set at 0.001. In
the non-parametric analysis the following allele sharing model was
used: multipoint, linear model, robdom and power=0.5. Because
the size of inheritance vectors of this family exceeded the limitation
of 21, we calculated LOD scores in which two unaffected individuals
(III:1 and III:2) were removed. Haplotype prediction was performed
using the ‘haplotype’ option in the multipoint linkage analysis of the
Allegro version 2.0 package.
Supporting Information
Figure S1 Parametric LOD Score Analysis of the SNP
Genotypes. Parametric LOD Score Analysis of the SNP
Genotypes. The SNP genotype data were analyzed by Allegro
and parametric LOD scores were generated for each autosomal
chromosome. Chromosomal location is shown along the X-axis.
Found at: doi:10.1371/journal.pone.0005687.s001 (2.38 MB EPS)
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